CO2018007621A2 - Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer - Google Patents

Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer

Info

Publication number
CO2018007621A2
CO2018007621A2 CONC2018/0007621A CO2018007621A CO2018007621A2 CO 2018007621 A2 CO2018007621 A2 CO 2018007621A2 CO 2018007621 A CO2018007621 A CO 2018007621A CO 2018007621 A2 CO2018007621 A2 CO 2018007621A2
Authority
CO
Colombia
Prior art keywords
risk
assess
compositions
methods
cancer occurrence
Prior art date
Application number
CONC2018/0007621A
Other languages
English (en)
Inventor
Jean-François Floch
Original Assignee
Syncerus S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncerus S A R L filed Critical Syncerus S A R L
Publication of CO2018007621A2 publication Critical patent/CO2018007621A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un método para evaluar el riesgo de aparición de cáncer en un individuo.
CONC2018/0007621A 2015-12-31 2018-07-23 Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer CO2018007621A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307190 2015-12-31
EP16305133 2016-02-05
PCT/EP2017/050034 WO2017114973A1 (en) 2015-12-31 2017-01-02 Compositions and methods for assessing the risk of cancer occurrence

Publications (1)

Publication Number Publication Date
CO2018007621A2 true CO2018007621A2 (es) 2018-10-22

Family

ID=57821944

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007621A CO2018007621A2 (es) 2015-12-31 2018-07-23 Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer

Country Status (17)

Country Link
US (2) US11085924B2 (es)
EP (1) EP3397965A1 (es)
JP (1) JP6940505B2 (es)
KR (1) KR102620651B1 (es)
CN (2) CN108700586A (es)
AU (1) AU2017204683B2 (es)
BR (1) BR112018013269A2 (es)
CA (1) CA3009768A1 (es)
CL (1) CL2018001788A1 (es)
CO (1) CO2018007621A2 (es)
EA (1) EA201891478A1 (es)
IL (1) IL260301A (es)
MA (1) MA43550A (es)
MX (1) MX2018008175A (es)
SG (1) SG11201804629XA (es)
TN (1) TN2018000197A1 (es)
WO (1) WO2017114973A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178354A1 (en) 2017-03-30 2018-10-04 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting lung cancer
ES2921775T3 (es) 2017-03-30 2022-08-31 Ecs Progastrin Sa Composiciones y métodos para detectar y tratar el cáncer de próstata que utilizan la molécula de unión a progastrina
WO2019110845A1 (en) 2017-12-08 2019-06-13 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
US20200400675A1 (en) * 2018-02-27 2020-12-24 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
DE69800716T2 (de) 1997-04-14 2001-09-20 Micromet Ges Fuer Biomedizinis Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2008513536A (ja) 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
CN101368966A (zh) * 2008-04-29 2009-02-18 北京科美东雅生物技术有限公司 一种胃泌素释放肽前体化学发光免疫分析测定试剂盒
AU2010306119A1 (en) * 2009-10-16 2012-05-03 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibodies to progastrin and their uses
AU2014203017B2 (en) * 2009-10-16 2017-02-02 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibodies to progastrin and their uses
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US9487582B2 (en) 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US20150071912A1 (en) 2010-03-24 2015-03-12 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
JP5726305B2 (ja) 2010-07-26 2015-05-27 レ ラボラトワール セルヴィエ 肝ガン治療のための方法及び組成物
US9410955B2 (en) * 2011-06-01 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for predicting the risk of developing a colonic neoplasia

Also Published As

Publication number Publication date
US20190011452A1 (en) 2019-01-10
US20210373027A1 (en) 2021-12-02
KR102620651B1 (ko) 2024-01-04
WO2017114973A1 (en) 2017-07-06
US11085924B2 (en) 2021-08-10
EA201891478A1 (ru) 2019-01-31
EP3397965A1 (en) 2018-11-07
JP2019505783A (ja) 2019-02-28
BR112018013269A2 (pt) 2018-12-11
MA43550A (fr) 2018-11-07
AU2017204683A1 (en) 2018-06-21
JP6940505B2 (ja) 2021-09-29
MX2018008175A (es) 2019-02-20
IL260301A (en) 2018-08-30
TN2018000197A1 (en) 2019-10-04
SG11201804629XA (en) 2018-07-30
CA3009768A1 (en) 2017-07-06
KR20180093973A (ko) 2018-08-22
CN114705858A (zh) 2022-07-05
AU2017204683B2 (en) 2023-03-16
CN108700586A (zh) 2018-10-23
CL2018001788A1 (es) 2018-09-21

Similar Documents

Publication Publication Date Title
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
HK1252055A1 (zh) 使用動態bh3分析評估毒性的組合物和方法
CO2018007621A2 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
CL2016001871A1 (es) Anticuerpos humanos para pd-1
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
BR112018000729A2 (pt) métodos e composições para o aprimoramento de traços de plantas
BR112017010871A2 (pt) método de impressão tridimensional de um objeto e objeto tridimensional
BR112017013838A2 (pt) composições de nanopartícula e métodos para imunoterapia
CL2016002375A1 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina y métodos que usan los mismos
ECSP17023281A (es) Inhibidores de mk2 y sus usos
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
BR112016019470A2 (pt) métodos e sistemas para retornar uma correção de posicionamento precoce
BR112015030351A2 (pt) método e aparelho para realização de transações locais
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
IL252686A0 (en) Pyrazolopyridineamines as inhibitors of mknk1 and mknk2
DK3324932T3 (da) Sammensætninger og fremgangsmåder for nanopartikel lyofile former
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112017006419A2 (pt) medições cinéticas de tau
BR112017021850A2 (pt) detecção de isoformas específicas de clusterina
BR112017019151A2 (pt) avaliação de risco para conclusões de operações de perfuração e de poço
BR112017008097A2 (pt) método para tratar condições oculares
PT107944A (pt) Marcadores tridimensionais para axiografia e determinação de valores individuais
CL2016002535A1 (es) Sistemas y métodos de sellado para miembros alargados